Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sST2/miR-223 as Biomarkers for SLIT Efficacy in HDM-Induced Allergic Rhinitis
NCT07436208Phase 1Completed
- Sponsor
- Zagazig University
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of standardized house dust mite extract in allergic rhinitis (AR), sponsored by Zagazig University. Primary endpoints: Number of participants with reduction in Relieve symptoms at 6 months, Total Nasal Symptom Score at 6 months and 1 more. Started Feb 2025; status: completed.
02
Drugs
standardized house dust mite extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07436208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436208.